Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Serogroup B
100%
Meningococcal Serogroup B
100%
Recombinant Vaccine
100%
Novel Recombinant
100%
Global Epidemiology
100%
Meningococcal Disease
40%
Serogroup Y
40%
Sepsis
20%
Europe
20%
Latin America (LATAM)
20%
Epidemiology
20%
National Program
20%
Vaccination Strategy
20%
Polysaccharide Vaccine
20%
Economic Impact
20%
Mass Vaccination
20%
Conjugate Vaccine
20%
Serogroup
20%
Case Fatality Rate
20%
Neisseria Meningitidis
20%
North America
20%
Neisseria Meningitidis Serogroup A
20%
Serogroup B Meningococcal Vaccine
20%
Armamentarium
20%
Meningitis
20%
Life-threatening Infections
20%
Safety Impact
20%
Early Efficacy
20%
Novel Protein
20%
Endemic Diseases
20%
Safety Effectiveness
20%
Serogroup A
20%
Safety Data
20%
Protein-based Vaccine
20%
Health Impact
20%
Early Safety
20%
Epidemic Disease
20%
Outer Membrane Vesicles
20%
Impact Data
20%
Disease Risk
20%
Serogroup C
20%
Social Impact
20%
Early Impact
20%
Specific Analysis
20%
Medicine and Dentistry
Cohort Effect
100%
Serotype
100%
Meningococcal Disease
100%
Recombinant Protein
100%
Sequela
22%
Disease
22%
Sepsis
11%
Infection
11%
Polysaccharide Vaccine
11%
Conjugate Vaccine
11%
Case Fatality Rate
11%
Neisseria meningitidis
11%
Mass Immunization
11%
Social Health
11%
Meningitis
11%
Outer Membrane
11%
Protein-Based Vaccine
11%
Membrane Vesicle
11%
Immunology and Microbiology
Serotype
100%
Conjugate Vaccine
11%
Neisseria meningitidis
11%
Polysaccharide Vaccine
11%
Membrane Vesicle
11%
Case Fatality Rate
11%
Outer Membrane
11%
Meningitis
11%